Macrogenics (MGNX) Current Assets (2012 - 2026)
Macrogenics (MGNX) posted quarterly Current Assets of $182.5 million for Q1 2026, little changed year-over-year from $182.1 million in Q1 2025, and down 17.01% quarter-over-quarter from $219.9 million in Q4 2025.
Macrogenics (MGNX) Current Assets (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Current Assets for 15 consecutive years, with $182.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets changed 0.24% year-over-year to $182.5 million; the TTM figure through Mar 2026 stood at $182.5 million (changed 0.24% YoY), while the FY2025 annual figure was $219.9 million, up 1.13% from the prior year.
- Current Assets slipped to $182.5 million in Q1 2026 per MGNX's latest filing, from $219.9 million in the prior quarter.
- Across five years, Current Assets topped out at $291.3 million in Q3 2023 and bottomed at $147.8 million in Q3 2022.
- Historically, Current Assets has averaged $215.5 million across 5 years, with a median of $218.2 million in 2022.
- Annual changes were most pronounced in 2022 — Current Assets plunged 55.84% — and 2023, when it soared 97.09%.
- Macrogenics' Current Assets stood at $222.2 million in 2022, then rose by 13.12% to $251.3 million in 2023, then decreased by 13.47% to $217.5 million in 2024, then rose by 1.13% to $219.9 million in 2025, then slipped by 17.01% to $182.5 million in 2026.
- Business Quant data shows MGNX's Current Assets at $182.5 million in Q1 2026, $219.9 million in Q4 2025, and $232.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 182.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 182.52 Mn |
| Dec 31, 2025 | 219.94 Mn |
| Sep 30, 2025 | 232.09 Mn |
| Jun 30, 2025 | 204.95 Mn |
| Mar 31, 2025 | 182.09 Mn |
| Dec 31, 2024 | 217.49 Mn |
| Sep 30, 2024 | 222.20 Mn |
| Jun 30, 2024 | 156.95 Mn |
| Mar 31, 2024 | 202.58 Mn |
| Dec 31, 2023 | 251.34 Mn |
| Sep 30, 2023 | 291.32 Mn |
| Jun 30, 2023 | 254.68 Mn |
| Mar 31, 2023 | 288.94 Mn |
| Dec 31, 2022 | 222.18 Mn |
| Sep 30, 2022 | 147.81 Mn |
| Jun 30, 2022 | 167.63 Mn |
| Mar 31, 2022 | 218.20 Mn |
| Dec 31, 2021 | 279.56 Mn |
| Sep 30, 2021 | 334.70 Mn |
| Jun 30, 2021 | 367.00 Mn |